The latter is also contained in many Fc-optimized mAbs like MOR00208 (anti-CD19 NCT01685021), Margetuximab (anti-Her2, NCT01828021), FLYSYN (anti-FLT3, ClinicalTrials.gov ID: NCT02789254), MEN1112 (anti-CD157, NCT02353143) and BI 836858 (anti-CD33, NCT02240706, NCT03013998) that are presently undergoing clinical evaluation, the latter three in AML. This evidence concerns the gene CD19 and acute myeloid leukemia.